nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.05.2015 | Headache (RB Halker, Section Editor)

CGRP Mechanism Antagonists and Migraine Management

verfasst von: Nazia Karsan, Peter J. Goadsby

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Migraine is a complex disorder of the brain that is common and highly disabling. As understanding of the neural pathways has advanced, and it has become clear that the vascular hypothesis does not explain the disorder, new therapeutic avenues have arisen. One such target is calcitonin gene-related peptide (CGRP)-based mechanisms. CGRP is found within the trigeminovascular nociceptive system widely from the trigeminal ganglion to second-order and third-order neurons and in regulatory areas in the brainstem. Studies have shown CGRP is released during severe migraine attacks and the reversal of the attack with effective triptan treatment normalizes those levels. CGRP administration triggers migraine in patients, and CGRP receptor antagonists have been shown to abort migraine. Here, we review the current state of CGRP mechanism antagonist therapy as its research and development is increasing in migraine therapeutics. We discuss several recent trials, highlighting the evidence base behind these novel drugs, and their potential future contribution to migraine management.

Amara SG, Jonas V, Rosenfeld MG, et al. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature. 1982;298(5871):240–4.CrossRefPubMed

Mulderry PK, Ghatei MA, Spokes RA, et al. Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience. 1988;25(1):195–205.CrossRefPubMed

3.••

Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6:573–82. An important review discussing the role of CGRP in migraine.CrossRefPubMed

Moore EL, Salvatore CA. Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine. Br J Pharmacol. 2012;166(1):66–78.CrossRefPubMedCentralPubMed

van Rossum D, Hanisch UK, Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev. 1997;21(5):649–78.CrossRefPubMed

Unger JW, Lange W. Immunohistochemical mapping of neurophysins and calcitonin gene-related peptide in the human brainstem and cervical spinal cord. J Chem Neuroanat. 1991;4(4):299–309.CrossRefPubMed

Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23(2):193–6.CrossRefPubMed

Zagami AS, Goadsby PJ, Edvinsson L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides. 1990;16(2):69–75.CrossRefPubMed

Goadsby EE. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183–87.CrossRefPubMed

10.

Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterising cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33:48–56.CrossRefPubMed

11.

Cernuda-Morollon E, Larrosa D, Ramon C, et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013;81(14):1191–6.CrossRefPubMed

12.

Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30(10):1179–86.CrossRefPubMed

13.

Sprenger T, Goadsby PJ. What has functional neuroimaging done for primary headache … and for the clinical neurologist? J Clin Neurosci: Off J Neurosurg Soc Australas. 2010;17(5):547–53.CrossRef

14.

Afridi SK, Matharu MS, Lee L, et al. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain. 2005;128:932–39.CrossRefPubMed

15.

Maniyar FH, Sprenger T, Monteith T, et al. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain. 2014;137(Pt 1):232–41.

16.••

Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurol. 2011;12:570–84. A review of the role of the brainstem in mediating the neuronal circuitry mechanism in migraine, current ideas regarding the pathophysiology of the condition and areas of the brain and circuitry that could be targeted with anti-migraine agents.CrossRef

17.

Edvinsson L, Ekman R, Jansen I, et al. Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. J Cereb blood flow Metab: Off J Int Soc Cereb Blood Flow Metab. 1987;7(6):720–8.CrossRef

18.

Arimura A. Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research. Regul Pept. 1992;37(3):287–303.PubMed

19.

Tuka B, Helyes Z, Markovics A, et al. Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia. 2013;33(13):1085–95.CrossRefPubMed

20.

Zagami AS, Edvinsson L, Goadsby PJ. Pituitary adenylate cyclase activating polypeptide (PACAP) and Migraine. Ann Clin Transl Neurol. 2014. in press.

21.

Lundberg JM, Franco-Cereceda A, Hua X, et al. Co-existence of substance P and calcitonin gene-related peptide-like immunoreactivities in sensory nerves in relation to cardiovascular and bronchoconstrictor effects of capsaicin. Eur J Pharmacol. 1985;108(3):315–9.CrossRefPubMed

22.

Uddman R, Edvinsson L, Ekman R, et al. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett. 1985;62(1):131–6.CrossRefPubMed

23.

Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med. 2007;13(1):39–44.CrossRefPubMed

24.

Evans BN, Rosenblatt MI, Mnayer LO, et al. CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors. J Biol Chem. 2000;275(40):31438–43.CrossRefPubMed

25.

Maniyar FH, Sprenger T, Schankin C, Goadsby PJ. Photic hypersensitivity in the premonitory phase of migraine- a positron emission topography study. Eur J Neurol. 2014;21:1178–83.CrossRefPubMed

26.

Eftekhari S, Edvinsson L. Possible sites of action of the new calcitonin gene-related peptide receptor antagonists. Ther Adv Neurol Disord. 2010;3(6):369–78.CrossRefPubMedCentralPubMed

27.

Lennerz JK, Ruhle V, Ceppa EP, et al. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol. 2008;507(3):1277–99.CrossRefPubMed

28.

Liu Y, Broman J, Zhang M, Edvinsson L. Brainstem and thalamic projections from a craniovascular sensory nervous centre in the rostral cervical spinal dorsal horn of rats. Cephalalgia. 2009;29(9):935–48.CrossRefPubMed

29.

Smith D, Hill RG, Edvinsson L, Longmore J. An immunocytochemical investigation of human trigeminal nucleus caudalis: CGRP, substance P and 5-HT1D-receptor immunoreactivities are expressed by trigeminal sensory fibres. Cephalalgia. 2002;22(6):424–31.CrossRefPubMed

30.

Strata P, Thach WT, Ottersen OP. New insights in cerebellar function. Introduction. Neuroscience. 2009;162(3):545–8.CrossRefPubMed

31.

Kawai Y, Takami K, Shiosaka S, et al. Topographic localization of calcitonin gene-related peptide in the rat brain: an immunohistochemical analysis. Neuroscience. 1985;15(3):747–63.CrossRefPubMed

32.

Brighina F, Palermo A, Panetta ML, et al. Reduced cerebellar inhibition in migraine with aura: a TMS study. Cerebellum (Lond, Engl). 2009;8(3):260–6.CrossRef

33.

Bahra A, Matharu MS, Buchel C, et al. Brainstem activation specific to migraine headache. Lancet. 2001;357(9261):1016–7.CrossRefPubMed

34.

Eftekhari S, Salvatore CA, Calamari A, et al. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience. 2010;169(2):683–96.CrossRefPubMed

35.

Edvinsson L. Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache: therapeutic implications. CNS Drugs. 2001;15(10):745–53.CrossRefPubMed

36.

Lynch Jr JJ, Regan CP, Edvinsson L, et al. Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteries. J Cardiovasc Pharmacol. 2010;55(5):518–21.CrossRefPubMed

37.

Bigal ME, Walter S. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs. 2014;28(5):389–99.CrossRefPubMed

38.

Doods H, Hallermayer G, Wu D, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol. 2000;129(3):420–3.CrossRefPubMedCentralPubMed

39.

Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350(11):1104–10.CrossRefPubMed

40.

Mallee JJ, Salvatore CA, LeBourdelles B, et al. Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J Biol Chem. 2002;277(16):14294–8.CrossRefPubMed

41.

Just S, Arndt K, Doods H. The role of CGRP and nicotinic receptors in centrally evoked facial blood flow changes. Neurosci Lett. 2005;381(1–2):120–4.CrossRefPubMed

42.

Petersen KA, Birk S, Lassen LH, et al. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia. 2005;25(2):139–47.CrossRefPubMed

43.

Edvinsson L, Linde M. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet. 2010;376(9741):645–55.CrossRefPubMed

44.

Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008;372(9656):2115–23.CrossRefPubMed

45.

Ho TW, Connor KM, Zhang Y, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology. 2014;83(11):958–66.CrossRefPubMed

46.

Ho TW, Ho AP, Chaitman BR, et al. Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease. Headache. 2012;52(2):224–35.CrossRefPubMed

47.

Connor KM, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009;73(12):970–7.CrossRefPubMedCentralPubMed

48.

Han TH, Blanchard RL, Palcza J, et al. Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults. J Clin Pharmacol. 2010;50(12):1367–76.CrossRefPubMed

49.

Ho AP, Dahlof CG, Silberstein SD, et al. Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia. 2010;30(12):1443–57.CrossRefPubMed

50.

Connor KM, Aurora SK, Loeys T, et al. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Headache. 2011;51(1):73–84.CrossRefPubMed

51.

Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011;31(6):712–22.CrossRefPubMed

52.

Diener HC, Barbanti P, Dahlof C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011;31(5):573–84.CrossRefPubMed

53.

Luo G, Chen L, Conway CM, et al. Discovery of BMS-846372, a potent and orally active human CGRP receptor antagonist for the treatment of migraine. ACS Med Chem Lett. 2012;3(4):337–41.CrossRefPubMedCentralPubMed

54.

Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo-controlled, dose-ranging trial. Cephalalgia. 2014;34(2):114–25.CrossRefPubMed

55.

Merck Sharp, Bohme Corp. A pharmacokinetic study of MK-1602 in the treatment of acute migraine (MK-1602-007) NCT01657370. https://clinicaltrials.gov/ct2/show/NCT01657370. Accessed 14 Mar 2015.

56.

Merck Sharp, Bohme Corp. A dose-finding study of MK-1602 in the treatment of acute migraine (MK-1602-006) NCT01613248. https://clinicaltrials.gov/ct2/show/NCT01613248. Accessed 14 Mar 2015.

57.

Edvinsson L. CGRP blockers in migraine therapy: where do they act? Br J Pharmacol. 2008;155(7):967–9.CrossRefPubMedCentralPubMed

58.

Hostetler ED, Joshi AD, Sanabria-Bohorquez S, et al. In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232. J Pharmacol Exp Ther. 2013;347(2):478–86.CrossRefPubMed

59.

Baumann A. Early development of therapeutic biologics—pharmacokinetics. Curr Drug Metab. 2006;7(1):15–21.CrossRefPubMed

60.••

Bigal ME, Walter S, Rapoport AM. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache. 2013;53(8):1230–44. An up to date current review on the anti-CGRP agents in migraine management, with a particular focus on the monoclonal antibodies.CrossRefPubMed

61.

Descotes J. Immunotoxicity of monoclonal antibodies. mAbs. 2009;1(2):104–11.CrossRefPubMedCentralPubMed

62.

Feuerstein G, Willette R, Aiyar N. Clinical perspectives of calcitonin gene related peptide pharmacology. Can J Physiol Pharmacol. 1995;73(7):1070–4.CrossRefPubMed

63.

Zeller J, Poulsen KT, Sutton JE, et al. CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat. Br J Pharmacol. 2008;155(7):1093–103.CrossRefPubMedCentralPubMed

64.

Alder biopharmaceuticals Inc. Safety tolerability and pharmacokinetics of ALD403 NCT01579383. https://clinicaltrials.gov/ct2/show/NCT01579383. Accessed 14 Mar 2015.

65.

Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13(11):1100–7.CrossRefPubMed

66.

Dodick DW, Goadsby PJ, Spierings EL, et al. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014;13(9):885–92.CrossRefPubMed

67.

Amgen. Ascending multiple-doses of AMG 334 in healthy subjects and in migraine patients NCT01723514. https://clinicaltrials.gov/ct2/show/NCT01723514. Accessed 14 Mar 2014.

68.

Amgen. Ascending single doses of AMG 334 in healthy subjects and migraine patients NCT01688739. https://www.clinicaltrials.gov/ct2/show/NCT01688739. Accessed 14 Mar 2015.

69.

Amgen. A phase 2 study to evaluate the efficacy and safety of AMG 334 in migraine prevention NCT01952574. https://clinicaltrials.gov/ct2/show/NCT01952574. Accessed 14 Mar 2015.

70.

Amgen. A study to assess the long-term safety and efficacy of AMG 334 in chronic migraine prevention NCT02174861. https://clinicaltrials.gov/ct2/show/NCT02174861. Accessed 14 Mar 2015.

71.

Bigal ME, Escandon R, Bronson M, et al. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase 1 program. Cephalalgia. 2013;34(7):483–92.CrossRefPubMed

72.

Teva Pharmaceutical Industries. A multicenter assessment of LBR-101 in high frequency episodic migraine NCT02025556. https://clinicaltrials.gov/ct2/show/NCT02025556. Accessed 14 Mar 2015.

73.

Teva Pharmaceutical Industries. Assessment of LBR-101 In chronic migraine NCT02021773. https://clinicaltrials.gov/ct2/show/NCT02021773. Accessed 14 Mar 2015.

74.

Walter S, Alibhoy A, Escandon R, Bigal ME. Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide. mAbs. 2014;6(4):871–8.CrossRefPubMed

75.

Bigal ME, Walter S, Bronson M, et al. Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. Cephalalgia 2014.

76.

Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain. 1994;117(Pt 3):427–34.CrossRefPubMed

77.

Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol. 2010;9(3):285–98.CrossRefPubMed

78.

Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004;44(5):414–25.CrossRefPubMed

79.

Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–9.CrossRefPubMed

Titel: CGRP Mechanism Antagonists and Migraine Management
verfasst von: Nazia Karsan
Peter J. Goadsby
Publikationsdatum: 01.05.2015
Verlag: Springer US
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 5/2015
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-015-0547-z

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2015

Development of Regional Stroke Programs

Clinical Utility of Ocular Vestibular-Evoked Myogenic Potentials (oVEMPs)

Palliative Care for Parkinson’s Disease: Has the Time Come?

Infantile-Onset Saccade Initiation Delay (Congenital Ocular Motor Apraxia)

Glutamate and GABA Imbalance Following Traumatic Brain Injury